221244-07-1

Basic information

• Product Name: 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 1-(1,1-dimethylethyl)-3-[4-(1,1-dimethylethyl)phenyl]-
• CAS NO: 221244-07-1
• Molecular Formula: C19H25N5
• Molecular Weight: 323.441
• Mol File: 221244-07-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 1-(1,1-dimethylethyl)-3-[4-(1,1-dimethylethyl)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 1-(1,1-dimethylethyl)-3-[4-(1,1-dimethylethyl)phenyl]-(221244-07-1)
• EPA Substance Registry System: 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 1-(1,1-dimethylethyl)-3-[4-(1,1-dimethylethyl)phenyl]-(221244-07-1)

Safety Data

• Hazardous Substances Data: 221244-07-1(Hazardous Substances Data)

Upstream product

• 862728-60-7 1-(1,1-dimethylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 158001-28-6 5-amino-1-(tert-butyl)-1H-pyrazole-4-carbonitrile 
• 221243-03-4 2-[(4-tert-butyl-phenyl)-methoxy-methylene]-malononitrile 
• 1710-98-1 p-tert-butyl benzoyl chloride 
• 98-73-7 4-(1,1-dimethylethyl)benzoic acid 
• 221243-74-9 C₁₈H₂₄N₄ 
• 77287-34-4 formamide 

Relevant articles and documents

Discovery of a potent protein kinase D inhibitor: insights in the binding mode of pyrazolo[3,4-d]pyrimidine analogues

In this study, we set out to rationally optimize PKD inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold. The lead compound for this study was 1-NM-PP1, which was previously found by us and others to inhibit PKD. In our screening we identified one compound (3-IN-PP1) displaying a 10-fold increase in potency over 1-NM-PP1, opening new possibilities for specific protein kinase inhibitors for kinases that show sensitivity towards pyrazolo[3,4-d]pyrimidine derived compounds. Interestingly the observed SAR was not in complete agreement with the commonly observed binding mode where the pyrazolo[3,4-d]pyrimidine compounds are bound in a similar fashion as PKD's natural ligand ATP. Therefore we suggest an alternate binding mode where the compounds are flipped 180 degrees. This possible alternate binding mode for pyrazolo[3,4-d]pyrimidine based compounds could pave the way for a new class of specific protein kinase inhibitors for kinases sensitive towards pyrazolo[3,4-d]pyrmidines.

MODULATION OF PROTEIN TRAFFICKING

Compounds and compositions are provided for treatment or amelioration of one or more disorders characterized by defects in protein trafficking. A method of treating a disorder characterized by impaired protein trafficking includes administering to a subject or contacting a cell with a compound of Formula I: [formula here] or pharmaceutically acceptable salts or derivatives thereof.